Explore more publications!
Nepal Healthcare Times
Got News to Share?

Nepal Healthcare Times: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Nepal Healthcare Times.

October 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

November 2025

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

December 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30 31

Press releases published on December 2, 2025

NewGen Reports Nine-Month 2025 Results with Balance Sheet Strengthened to $66.75 Net Asset Value Per Share
December 2, 2025

NewGen Reports Nine-Month 2025 Results with Balance Sheet Strengthened to $66.75 Net Asset Value Per Share

Indeterminate GlobeNewswire
Three Trailblazing Women in Health Care Honoured with the Medal of the Member of the National Assembly
December 2, 2025

Three Trailblazing Women in Health Care Honoured with the Medal of the Member of the National Assembly

Indeterminate GlobeNewswire
Trois femmes pionnières en soins de santé récompensées par une Médaille de l’Assemblée nationale
December 2, 2025

Trois femmes pionnières en soins de santé récompensées par une Médaille de l’Assemblée nationale

Indeterminate GlobeNewswire
Clearmind Medicine Advances CMND-100 to Dosing Phase at Hadassah Medical Center in Ongoing Phase I/IIa Clinical Trial for Alcohol Use Disorder
December 2, 2025

Clearmind Medicine Advances CMND-100 to Dosing Phase at Hadassah Medical Center in Ongoing Phase I/IIa Clinical Trial for Alcohol Use Disorder

Indeterminate GlobeNewswire
Polyrizon Announces Successful Completion of Key Manufacturing Upscaling Milestone for Its Nasal Spray Platform
December 2, 2025

Polyrizon Announces Successful Completion of Key Manufacturing Upscaling Milestone for Its Nasal Spray Platform

Indeterminate GlobeNewswire
Zevra Therapeutics, Inc. Appoints Alicia Secor to Board of Directors; Announces Retirement of Wendy Dixon, PhD
December 2, 2025

Zevra Therapeutics, Inc. Appoints Alicia Secor to Board of Directors; Announces Retirement of Wendy Dixon, PhD

Indeterminate GlobeNewswire
NRx Pharmaceuticals (NASDAQ: NRXP) and HOPE Therapeutics to Host Corporate Update Call
December 2, 2025

NRx Pharmaceuticals (NASDAQ: NRXP) and HOPE Therapeutics to Host Corporate Update Call

Indeterminate GlobeNewswire
BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS® 2025
December 2, 2025

BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS® 2025

Indeterminate GlobeNewswire
Nkarta to Participate in Evercore Healthcare Conference
December 2, 2025

Nkarta to Participate in Evercore Healthcare Conference

Indeterminate GlobeNewswire
Pluristyx Launches Organoid COMMONS, Uniting Industry Leaders to Revolutionize Drug Discovery
December 2, 2025

Pluristyx Launches Organoid COMMONS, Uniting Industry Leaders to Revolutionize Drug Discovery

Indeterminate GlobeNewswire
Ventyx Provides Clinical and Corporate Updates
December 2, 2025

Ventyx Provides Clinical and Corporate Updates

Indeterminate GlobeNewswire
Fennec Pharmaceuticals Announces Positive Topline Results From Investigator-Initiated Clinical Study of PEDMARK® in Japan to Reduce Cisplatin-Induced Hearing Loss
December 2, 2025

Fennec Pharmaceuticals Announces Positive Topline Results From Investigator-Initiated Clinical Study of PEDMARK® in Japan to Reduce Cisplatin-Induced Hearing Loss

Indeterminate GlobeNewswire
CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB)
December 2, 2025

CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB)

Indeterminate GlobeNewswire
Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock
December 2, 2025

Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock

Indeterminate GlobeNewswire
Fractyl Health Reports Positive 6-Month REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita® Procedure
December 2, 2025

Fractyl Health Reports Positive 6-Month REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita® Procedure

Indeterminate GlobeNewswire
Comanche Biopharma Appoints Richard Colvin, MD, PhD as Global Head of R&D and John McHutchison, AO, MD as Chairman and Director of Comanche Biopharma Australia
December 2, 2025

Comanche Biopharma Appoints Richard Colvin, MD, PhD as Global Head of R&D and John McHutchison, AO, MD as Chairman and Director of Comanche Biopharma Australia

Indeterminate GlobeNewswire
Jasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in Asthma and Findings from BEACON Study Internal Investigation
December 2, 2025

Jasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in Asthma and Findings from BEACON Study Internal Investigation

Indeterminate GlobeNewswire
Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer
December 2, 2025

Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer

Indeterminate GlobeNewswire
Tiziana Life Sciences Plans to Spinout IL-6 Asset into Separate Listed Company
December 2, 2025

Tiziana Life Sciences Plans to Spinout IL-6 Asset into Separate Listed Company

Indeterminate GlobeNewswire
Hydreight Technologies Announces Corporate Update Highlighting Q3 Momentum, VSDHOne Acceleration, and 2026 Outlook
December 2, 2025

Hydreight Technologies Announces Corporate Update Highlighting Q3 Momentum, VSDHOne Acceleration, and 2026 Outlook

Indeterminate GlobeNewswire
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions